Alterations of hypothalamic neuropeptides involved in food intake and appetite in olanzapine monotherapy

Download

index.pdf

Date

2012

Author

Sezlev, Deniz

Metadata

Show full item record

Item Usage Stats

108
views

41
downloads

The mechanism of weight gain due to treatment with olanzapine, a serotonin receptor antagonist, has not been fully understood. Weight gain and food intake are under the control of neuropeptides/hormones, POMC (proopiomelanocortin), CART (cocaine and amphetamine regulated transcript), AgRP (Agouti-related peptide) and NPY (neuropeptide Y) that are synthesized and secreted from the arcuate nucleus (ARC) of hypothalamus. In this study, the altereration of the ARC neuropeptide/hormone levels both in humans and rats were determined as one of the weight gain mechanism. To examine olanzapine’s weight gain effects, male first attack psychotic patients (pre-treatment), were hospitalized and treated for 4 -weeks (post-treatment), (n = 22), and healthy control group (n = 26) were included to the study. Case-control association design was used to analyze the changes in body mass index (BMI), peripheral leptin and the ARC neuropeptides levels. In patients, after 4-weeks of the olanzapine treatment; BMI and the waist circumference were significantly increased with average weight gain of 4.33 kg. In pre-treatment group, NPY levels were significantly lower while α-MSH, the anorexigenic product of POMC levels were significantly higher vs. control. At post-treatment, both leptin and NPY levels were significantly increased but the CART levels did not change. To further understand the underlying mechanism of olanzapine induced weight gain, the drug was orally administrated to 10 healthy male Wistar rats to analyze both the hypotalamic gene expression and peripheral levels of those candidate neuropeptides. In rats food consumption was increased and hypotalamic mRNA levels of NPY, AgRP and POMC were decreased while CART levels did not show any alteration. Consistent with the expression data, circulating levels of NPY, AgRP and α-MSH decreased significantly but CART levels were also reduced unexpectedly. In conclusion, it may be presumed that the antagonistic effect of olanzapine on the ARC neurons might be the basis for a disregulation of the neurohormones secretion which may cause weight gain in the treated psychotic patients.

Subject Keywords

Hypothalamic hormones., Olanzapine., Neuropeptides., Weight gain.

URI

http://etd.lib.metu.edu.tr/upload/12614593/index.pdf
https://hdl.handle.net/11511/21753

Collections

Graduate School of Natural and Applied Sciences, Thesis

Suggestions

OpenMETU
Core

Determination of hypothalamic neuropeptide levels involved in appetite regulation in atypical antipsychotic drug, risperidone treatment Kurşungöz, Canan; Yanık, Tülin; Department of Biology (2012) Although the use of atypical antipsychotic drugs is successful in the treatment of schizophrenia, they cause complications in the long term use that is mainly weight gain. In this study, circulating levels of hypothalamic neuropeptides/hormones, which are related to appetite regulation; neuropeptide Y (NPY), alpha melanocyte stimulating hormone (α-MSH), cocaine and amphethamine regulated transcript (CART) and plus leptin in male schizophrenic patients who were treated with an atypical antipsychotic drug, ri...
Dysregulation of hypothalamic modulation in olanzapine treated male rats Sezlev-Bilecen, Deniz; AK, MEHMET; Yanık, Tülin (Elsevier BV, 2016-11-03) The mechanism of weight gain through application of olanzapine, a serotonin and dopamine receptor antagonist has not been fully understood. Weight gain and food intake are under the control of various neurohormones; POMC (proopiomelanocortin), CART (cocaine and amphetamine regulated transcript), AgRP (Agouti-related peptide) and NPY (neuropeptide Y) that are majorly synthesized and secreted from the arcuate nucleus (ARC) of hypothalamus. In this study, the alteration of the ARC neurohormone levels in rats w...
Detection of hypothalamic neuropeptite levels involved in appetite regulation in aripiprazole treatment / Özdemir, Serhat; Yanık, Tülin; Department of Biotechnology (2014) Disruption or malfunctioning of neurotransmitter pathways, especially serotonergic and dopaminergic pathways are closely related to psychotic disorders such as schizophrenia. Antipsychotic medications are becoming widespread; however, in long term treatments, these drugs lead to considerable amount of weight gain as a side effect. Metformin, an antidiabetic drug, has previously been used to treat antipsychotic induced weight gain and aripiprazole has been defined as a neutral antipsychotic drug in terms of ...
The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: Olanzapine monotherapy AK, MEHMET; Sezlev, Deniz; Sutcigil, Levent; Akarsu, Suleyman; Ozgen, Fuat; Yanık, Tülin (2013-03-01) The mechanism underlying the weight gain due to treatment with olanzapine and other second generation antipsychotics has not been fully understood. To examine olanzapine's weight gain effects, we accepted first attack psychotic patients with no medication (pre-treatment) (n = 22) and the healthy control group (n = 26) in this study. After patient diagnosis, they were hospitalized and then treated for four weeks with olanzapine (post-treatment). We used case-control association design to test body mass index...
Effects of risperidone treatment on the expression of hypothalamic neuropeptide in appetite regulation in Wistar rats Kursungoz, Canan; AK, MEHMET; Yanık, Tülin (2015-01-30) Although the use of atypical antipsychotic drugs has been successful in the treatment of schizophrenia, they can cause some complications in the long-term use, including weight gain. Patients using these drugs tend to disrupt treatment primarily due to side effects. The atypical antipsychotic mechanism of action regulates a number of highly disrupted neurotransmitter pathways in the brains of psychotic patients but may also cause impairment of neurohorrnonal pathways in different brain areas. In this study,...

Citation Formats

D. Sezlev, “Alterations of hypothalamic neuropeptides involved in food intake and appetite in olanzapine monotherapy,” M.S. - Master of Science, Middle East Technical University, 2012.